Nahla Azzam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nahla Azzam has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Othman Alharbi
Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia
10 shared publications Abdulrahman Aljebreen
Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
8 shared publicationsMajid A. Almadi
6 shared publications- Abdulrahman Aljebreen
Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia,
2 shared publications - Majid Abdularahman Almadi
Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
2 shared publications Muhanad O. Eltayeb
2 shared publications
Latest Publications
- Open Access
- 4 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6929
Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
The prevalence of ulcerative colitis (UC) in the Middle East is increasing, impacting the economic and healthcare burden. The management of patients with mild to moderate UC is still a challenge as several factors can affect optimal care, including drug choice, induction and maintenance dose, treatment optimization and de-escalation, therapy duration, monitoring, and safety profile. We conducted an expert consensus to standardize the management of patients with mild to moderate UC. Sixteen experts in inflammatory bowel diseases, through a well-established and accepted Delphi methodology, voted and approved eight statements in order to provide practical guidance to clinicians in the Middle East.
- 4 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6929
Open AccessTreatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
The prevalence of ulcerative colitis (UC) in the Middle East is increasing, impacting the economic and healthcare burden. The management of patients with mild to moderate UC is still a challenge as several factors can affect optimal care, including drug choice, induction and maintenance dose, treatment optimization and de-escalation, therapy duration, monitoring, and safety profile. We conducted an expert consensus to standardize the management of patients with mild to moderate UC. Sixteen experts in inflammatory bowel diseases, through a well-established and accepted Delphi methodology, voted and approved eight statements in order to provide practical guidance to clinicians in the Middle East.
- Open Access
- 18 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4157
Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study
Background: The advent of monoclonal antibodies (mAbs) has revolutionized the management of many immune-mediated diseases such as inflammatory bowel disease (IBD). Infliximab and adalimumab were the first mAbs approved for the management of IBD, and are still commonly prescribed for the treatment of both Crohn’s disease (CD) and ulcerative colitis (UC). Although mAbs have demonstrated high effectiveness rates in the management of IBD, some patients fail to respond adequately to mAbs, resulting in disease progression and the flare-up of symptoms. Objective: The objective was to explore the predictors of treatment failure among IBD patients on infliximab (INF) and adalimumab (ADA)—as demonstrated via colonoscopy with a simple endoscopic score (SES–CD) of ≥1 for CD and a Mayo score of ≥2 for UC—and compare the rates of treatment failure among patients on those two mAbs. Methods: This was a prospective cohort study among IBD patients aged 18 years and above who had not had any exposure to mAbs before. Those patients were followed after the initiation of biologic treatment with either INF or ADA until they were switched to another treatment due to failure of these mAbs in preventing the disease progression. Univariate and multiple logistic regressions were conducted to examine the predictors and rates of treatment failure. Results: A total of 146 IBD patients (118 patients on INF and 28 on ADA) met the inclusion criteria and were included in the analysis. The mean age of the patients was 31 years, and most of them were males (59%) with CD (75%). About 27% and 26% of the patients had penetrating and non-stricturing–non-penetrating CD behavior, respectively. Patients with UC had significantly higher odds of treatment failure compared to their counterparts with CD (OR = 2.58, 95% CI [1.06–6.26], p = 0.035). Those with left-sided disease had significantly higher odds of treatment failure (OR = 4.28, 95% CI [1.42–12.81], p = 0.0094). Patients on ADA had higher odds of treatment failure in comparison to those on INF (OR = 26.91, 95% CI [7.75–93.39], p = 0.0001). Conclusion: Infliximab was shown to be more effective in the management of IBD, with lower incidence rates of treatment failure in comparison to adalimumab.
- 18 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4157
Open AccessPredictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study
Background: The advent of monoclonal antibodies (mAbs) has revolutionized the management of many immune-mediated diseases such as inflammatory bowel disease (IBD). Infliximab and adalimumab were the first mAbs approved for the management of IBD, and are still commonly prescribed for the treatment of both Crohn’s disease (CD) and ulcerative colitis (UC). Although mAbs have demonstrated high effectiveness rates in the management of IBD, some patients fail to respond adequately to mAbs, resulting in disease progression and the flare-up of symptoms. Objective: The objective was to explore the predictors of treatment failure among IBD patients on infliximab (INF) and adalimumab (ADA)—as demonstrated via colonoscopy with a simple endoscopic score (SES–CD) of ≥1 for CD and a Mayo score of ≥2 for UC—and compare the rates of treatment failure among patients on those two mAbs. Methods: This was a prospective cohort study among IBD patients aged 18 years and above who had not had any exposure to mAbs before. Those patients were followed after the initiation of biologic treatment with either INF or ADA until they were switched to another treatment due to failure of these mAbs in preventing the disease progression. Univariate and multiple logistic regressions were conducted to examine the predictors and rates of treatment failure. Results: A total of 146 IBD patients (118 patients on INF and 28 on ADA) met the inclusion criteria and were included in the analysis. The mean age of the patients was 31 years, and most of them were males (59%) with CD (75%). About 27% and 26% of the patients had penetrating and non-stricturing–non-penetrating CD behavior, respectively. Patients with UC had significantly higher odds of treatment failure compared to their counterparts with CD (OR = 2.58, 95% CI [1.06–6.26], p = 0.035). Those with left-sided disease had significantly higher odds of treatment failure (OR = 4.28, 95% CI [1.42–12.81], p = 0.0094). Patients on ADA had higher odds of treatment failure in comparison to those on INF (OR = 26.91, 95% CI [7.75–93.39], p = 0.0001). Conclusion: Infliximab was shown to be more effective in the management of IBD, with lower incidence rates of treatment failure in comparison to adalimumab.
- Open Access
- 9 April 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 616204
NOTCH Single Nucleotide Polymorphisms in the Predisposition of Breast and Colorectal Cancers in Saudi Patients
Breast cancer (BC) is a heterogeneous disease and is one of the most common malignancy affecting women worldwide while colorectal cancer (CRC) is estimated to be the third common cancer and second leading cause of cancer related death globally. Both BC and CRC involve multiple genetic and epigenetic alterations in genes belonging to various signaling pathways including NOTCH that has been implicated in the development of these cancers. We investigated four single nucleotide polymorphisms, each in genes encoding NOTCH1-4 receptors for their role in susceptibility to breast and colorectal cancers in Saudi population. In this case-control study, TaqMan genotypic analysis of rs3124591 in NOTCH1 and rs3820041 in NOTCH4 did not exhibit association with breast as well as colorectal cancers. However, a strong association of rs11249433 which is in close proximity to NOTCH2 was observed with breast cancer susceptibility especially with those having an early onset of the disease. Interestingly, the rs1043994 located in NOTCH3 showed gender preference and was found to be significantly associated with colorectal cancers in males. Validation of these findings in bigger populations of different ethnicities may prove beneficial in identifying rs11249433 and rs1043994 as genetic screening markers for early detection of breast and colorectal carcinomas, respectively.
- 9 April 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 616204
Open AccessNOTCH Single Nucleotide Polymorphisms in the Predisposition of Breast and Colorectal Cancers in Saudi Patients
Breast cancer (BC) is a heterogeneous disease and is one of the most common malignancy affecting women worldwide while colorectal cancer (CRC) is estimated to be the third common cancer and second leading cause of cancer related death globally. Both BC and CRC involve multiple genetic and epigenetic alterations in genes belonging to various signaling pathways including NOTCH that has been implicated in the development of these cancers. We investigated four single nucleotide polymorphisms, each in genes encoding NOTCH1-4 receptors for their role in susceptibility to breast and colorectal cancers in Saudi population. In this case-control study, TaqMan genotypic analysis of rs3124591 in NOTCH1 and rs3820041 in NOTCH4 did not exhibit association with breast as well as colorectal cancers. However, a strong association of rs11249433 which is in close proximity to NOTCH2 was observed with breast cancer susceptibility especially with those having an early onset of the disease. Interestingly, the rs1043994 located in NOTCH3 showed gender preference and was found to be significantly associated with colorectal cancers in males. Validation of these findings in bigger populations of different ethnicities may prove beneficial in identifying rs11249433 and rs1043994 as genetic screening markers for early detection of breast and colorectal carcinomas, respectively.
- Open Access
- 1 January 2020
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 26 (5) , 256-262
Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 1 January 2020
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 26 (5) , 256-262
Open AccessDisability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S823
Plasma Ghrelin and Leptin in Patients with Inflammatory Bowel Disease and its Association with Nutritional Status
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S823
Plasma Ghrelin and Leptin in Patients with Inflammatory Bowel Disease and its Association with Nutritional Status
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB620
Tu1597 Predictors of Failure of Endoscopic Retrograde Cholangiopancreatography in Clearing Bile Duct Stones
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB620
Tu1597 Predictors of Failure of Endoscopic Retrograde Cholangiopancreatography in Clearing Bile Duct Stones
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1061 Diverticular Disease in Saudi Arabia: Prevalence, Distribution, Association and Clinical Feature
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1061 Diverticular Disease in Saudi Arabia: Prevalence, Distribution, Association and Clinical Feature
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB224
Sa1490 The Use of Self-Expandable Esophageal Stents in the Management of Stapler Line Leaks Complicating Laparoscopic Sleeve Gastrectomy
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB224
Sa1490 The Use of Self-Expandable Esophageal Stents in the Management of Stapler Line Leaks Complicating Laparoscopic Sleeve Gastrectomy
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1423 Clinical Predictors of Resectability of Pancreatic Adenocarcinoma
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1423 Clinical Predictors of Resectability of Pancreatic Adenocarcinoma